(Bold for FDA approved)
How Loxacon works• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Although classified as a conventional antipsychotic, loxapine is a potent serotonin 2A antagonist
• Serotonin 2A antagonist properties might be relevant at low doses, but generally are overwhelmed by high dosing
• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior
Notable Side Effects• Neuroleptic-induced deficit syndrome
• Akathisia
• Drug-induced parkinsonism
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Rare tachycardia
• Galactorrhea, amenorrhea
• Sedation
• Dry mouth, constipation, vision disturbance, urinary retention
• Hypotension, tachycardia
Life Threatening Side Effects• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Rare agranulocytosis
• Rare hepatocellular injury
• Rare seizures
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis
• Bronchospasm, with the potential to lead to respiratory distress and respiratory arrest (inhalant)

unusual

common
• Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Reduce the dose
• For sedation, give at night
• Switch to an atypical antipsychotic
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• 60–100 mg/day in divided doses
Dosage Forms• Capsule 6.8 mg loxapine succinate equivalent to 5 mg loxapine, 13.6 mg loxapine succinate equivalent to 10 mg loxapine, 34.0 mg loxapine succinate equivalent to 25 mg loxapine, 68.1 mg loxapine succinate equivalent to 50 mg loxapine
• Oral liquid 25 mg/mL (discontinued in USA)
• Injection 50 mg/mL (discontinued in USA)
• Inhalant 10 mg unit in a single-use inhaler
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• No
Renal Impairment• Use with caution
Hepatic Impairment• Use with caution
Cardiac Impairment• Use with caution
Elderly• Some patients may tolerate lower doses better
• Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
Children and Adolescents• Safety and efficacy not established
• Generally, consider second-line after atypical antipsychotics
Pregnancy• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Controlled studies have not been conducted in pregnant women
• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Renal papillary abnormalities have been seen in rats during pregnancy
• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary
• Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy
Breast Feeding• Unknown if loxapine is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera